Oyster Point Pharma to go public

Princeton, New Jersey-based Oyster Point Pharma, a clinical-stage biopharmaceutical company focusing on treating ocular surface diseases, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. The company plans on listing the stock on the NASDAQ under the ticker symbol "OYST." J.P. Morgan Securities LLC, Cowen & Company LLC and Piper Jaffray & Co. will serve as the lead underwriters. Oyster Point's backers include Invus Opportunities and Flying L Partners.

DealsNorth AmericaUSBriefs